Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. (NNVC) generates frequent news as a clinical stage biotechnology company focused on nanomedicine-based antiviral drug candidates. Its updates center on the development and regulatory progress of NV-387, a broad-spectrum antiviral that the company states is designed to mimic host cell attachment receptors such as sulfated proteoglycans, aiming to trap and neutralize a wide range of human pathogenic viruses.
News coverage for NanoViricides often highlights clinical and regulatory milestones. Recent announcements include approval by the regulatory agency ACOREP in the Democratic Republic of Congo to start a Phase II clinical trial of NV-387 for MPox, ongoing work toward a Phase II trial for viral acute and severe acute respiratory infections (viral ARI/SARI), and preparations for orphan drug designation applications for MPox, Smallpox, and Measles. The company also reports on its Phase I safety results for NV-387 and describes its efforts to advance NV-387 into Phase II human clinical trials.
Investors and observers following NNVC news can expect detailed discussions of preclinical and clinical data in animal models and early human studies, including comparisons of NV-387 to existing antivirals such as oseltamivir, baloxavir, peramivir, remdesivir, and tecovirimat. Press releases frequently address emerging viral threats, such as influenza A/H3N2 variants, H5N1 bird flu, MPox clades, coronaviruses, RSV, and Measles, and position NV-387 within these contexts.
NanoViricides also issues news on financing events, such as registered direct offerings and concurrent private placements, which support its research and development plans. Additional coverage includes presentations at investor and partnering conferences, shareholder meeting announcements, and commentary from company leadership on the potential role of nanoviricide technology in pandemic preparedness and bioterrorism response. Bookmark this page to review ongoing NNVC news as the company reports new data, regulatory interactions, and corporate developments.
NanoViricides, a leader in antiviral nanomedicines, presents the progress of its drug candidate NV-387, which has completed Phase I clinical trials with no adverse events reported. NV-387 has demonstrated significant efficacy against various viruses, including RSV, Influenza, and coronavirus, in preclinical studies. The company plans to advance NV-387 to Phase II trials, targeting pediatric RSV treatment. NanoViricides estimates a potential market size of $16 billion in three years for diseases NV-387 aims to treat. Additionally, the company is developing NV-HHV-1 for herpesvirus-related conditions and possesses a cGMP-compliant manufacturing facility, supporting its clinical and market entry plans.
NanoViricides has announced that its antiviral candidate NV-387 shows promising results against the H5N1 bird flu virus. This drug demonstrated superiority over existing treatments like Oseltamivir, Peramivir, and Baloxavir in a model of Influenza A/H3N2 infection. NV-387 not only prevents viral and immune damage to the lungs but also targets the viral MBS site, which is common in HPAI H5N1. This adaptability means NV-387 is likely to remain effective despite viral mutations. The increasing spread of H5N1 among mammals and potential for human infection underscores the need for such treatments. NanoViricides is advancing NV-CoV-2 for COVID-19 and other antiviral candidates, although exact clinical trial dates remain uncertain due to dependency on collaborators and consultants.
NanoViricides reports that its antiviral NV-387 has shown efficacy in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model. NV-387, both orally and intravenously, significantly reduced lung cell infiltration and mucus load compared to untreated controls. Oral treatment resulted in 31% lung infiltration, and intravenous treatment showed 22%, against 68% for untreated controls. Similarly, mucus index values were 53 (oral) and 32 (intravenous) versus 138 for untreated controls. NV-387 improved survival by 88%, surpassing the 25%-38% improvement by approved drugs Oseltamivir, Rapivab, and Baloxavir. Phase I clinical trials demonstrated no adverse events, positioning NV-387 for Phase II trials. Furthermore, NV-387’s host-mimetic design minimizes the likelihood of viral resistance, unlike other drugs.
NanoViricides announced positive preclinical results for its lead nanomedicine drug candidate, NV-387, which demonstrates an ideal flat blood concentration profile upon oral administration in animal models. This profile allows sustained antiviral effects, requiring less frequent dosing. In both rat and dog models, blood concentrations of NV-387 peaked in one hour and remained stable for eight hours, declining to baseline after twelve hours. After repeated doses, the drug's concentration plateaued for 24 hours, extending to 36 hours before returning to baseline. NV-387 showed efficacy in treating various viral infections, including RSV, COVID-19, and Influenza, and outperformed existing therapeutics. Clinical safety studies of NV-387 in Phase I human trials revealed no adverse events. The company aims to advance NV-387 into Phase II trials for RSV treatment.
NanoViricides announced a significant advancement in its lead antiviral agent, NV-387. This drug, designed for broad-spectrum antiviral treatment, has shown prolonged blood concentration levels in non-human primate models, indicating the potential for infrequent dosing. NV-387's unique polymeric design helps sustain drug levels, making it effective for moderate to severe viral infections like RSV, COVID, and influenza. The drug demonstrated superior performance over existing antiviral drugs in preclinical studies and is expected to proceed to Phase II clinical trials for RSV.
NanoViricides, a leader in broad-spectrum antiviral nanomedicines, has developed NV-387, a first-in-class antiviral agent targeting RSV, COVID-19, Influenza, and other viruses. NV-387 employs novel host-mimetic technology to remain effective despite viral mutations. It has outperformed existing drugs such as remdesivir, Tamiflu, and TPOXX in preclinical studies. NV-387 has successfully completed Phase I human trials with no reported adverse events, demonstrating strong safety profiles. The drug is now poised for Phase II trials. NanoViricides holds exclusive perpetual licenses for several antiviral treatments and collaborates with Karveer Meditech in India.
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wide range of viruses, including COVID-19, RSV, Influenza, and Smallpox. The drug's mechanism of action prevents viruses from escaping, even as they mutate.
NV-387 is available in oral syrup, gummy, and injectable forms, addressing various patient needs. The collaboration with Aagami is expected to enhance NanoViricides' business development and licensing efforts while allowing the company to focus on advancing its clinical trials.
NanoViricides has announced promising results for its broad-spectrum antiviral NV-387 in treating lethal RSV infections in animal models. When administered orally, NV-387 completely protected the animals, showing no lung damage and indicating a potential cure for RSV. Comparatively, animals treated with ribavirin showed severe lung damage and did not survive. NV-387 demonstrated efficacy with no adverse events in prior human trials and is set to progress to Phase II clinical trials. With no current approved safe treatment for RSV, NV-387 could address significant unmet medical needs, especially in vulnerable populations like infants and the elderly.
NanoViricides reported filing its Quarterly Report for the fiscal second quarter ending March 31, 2024. The report was submitted to the SEC on May 14, 2024. As of March 31, the company had $3.51 million in cash and equivalents, with an additional $2.5 million available, totaling $6 million. Property and equipment assets were reported at $7.92 million, with total liabilities standing at $0.81 million. The company utilized $4.84 million in net cash over nine months. Management voiced concerns about maintaining operations for the next 12 months without additional financing. NV-387, designed for broad-spectrum antiviral activity, is advancing to Phase II clinical trials for treating RSV under the US FDA. The Phase I trial for NV-CoV-2 (NV-387) in India concluded successfully, but the COVID treatment segment was incomplete due to a lack of patients. NanoViricides is seeking additional funding and exploring partnerships for NV-387, projecting significant market potential for their drug pipeline targeting various viral infections.
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause of hospitalizations and deaths among children under 5 and adults over 65. The company's NV-387 is aimed to provide a safer and more effective treatment option for these vulnerable groups.
The company has completed Phase 1a/1b human clinical trials for NV-387 with no reported adverse events and plans to advance to Phase II trials for RSV treatment.